Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to commercialize Titan’s Probuphine in Canada.
Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention, as well as helping to prevent accidental pediatric exposure.
The Psychopharmacologic Drugs Advisory Committee of the FDA recently voted 12-to-5 in favor of approving Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction. The FDA has set an action PDUFA date for Feb. 27.
Probuphine was developed using Titan’s ProNeura continuous drug delivery system, which consists of a small, solid implant made from a mixture of ethylene-vinyl acetate and a drug substance.
Under terms of the sublicense agreement, Knight will also handle all ongoing regulatory and commercial activities for Probuphine in Canada.
“Partnering with Knight Therapeutics is another step in our vision to making a lasting impact on how this chronic disease is treated in North America,” Behshad Sheldon, president and CEO of Braeburn, said in a statement.